Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

211 questions · 212 findings · 75 reviews

No studies found 44 · 20.8%GRADE not reported 17 · 8%Very low 70 · 33%Low 49 · 23.1%Moderate 28 · 13.2%High 4 · 1.9%

Summary of findings: continuous cycles alternating aztreonam lysine for inhalation with tobramycin for inhalation solution vs continuous cycles alternating placebo with tobramycin

Adverse events: any adverse event in the comparative phase · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

Summary of findings: continuous cycles alternating aztreonam lysine… showed no clear difference in adverse events: any adverse event in the comparative phase compared with continuous cycles alternating placebo with tobramycin (low certainty).

1 finding from 1 review

Summary of findings: amikacin liposome inhalation suspension (ALIS) vs tobramycin

Number experiencing adverse effects · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

Summary of findings: amikacin liposome inhalation suspension (ALIS) showed no clear difference in adverse events: number of participants experiencing any TEAE compared with tobramycin (moderate certainty).

1 finding from 1 review

Intervention not reported

Incidence of adverse events ‐ co‐trimoxazole prophylaxis only · children with HIV infection aged 12 years and under

The intervention showed no clear difference in incidence of adverse events ‐ co‐trimoxazole prophylaxis only (moderate certainty).

1 finding from 1 review

Summary of findings: monoclonal antibody KB001‐A vs placebo

Number experiencing adverse effects · children (12 or over) and adults with cystic fibrosis and lung infection

It is very uncertain whether summary of findings: monoclonal antibody KB001‐A changes adverse events number of participants experiencing adverse events compared with placebo (very low certainty).

1 finding from 1 review

Doxycycline vs quinolones

Adverse events (Analysis 1.7) Participant's report · men and non‐pregnant women with symptomatic (uterine cervicitis and urethritis), or asymptomatic genital CT infection, diagnosed by cell…

It is very uncertain whether doxycycline changes adverse events Men and women Assessed by participants' self‐report compared with quinolones (very low certainty).

1 finding from 1 review

Zinc vs placebo

Adverse events number of participants hospitalised during the trial · children with cystic fibrosis

Summary of findings: Zinc supplementation showed no clear difference in adverse events number of participants hospitalised during the trial compared with placebo (moderate certainty).

1 finding from 1 review

Quinolone vs macrolides

Quality of life Drug resistance/microbial sensitivity Serious adverse events Lung function Hospitalisations Adverse events/side effects Number of participants colonised with P aeruginosa · patients with chronic obstructive pulmonary disease

The review found no eligible studies for this question.

1 finding from 1 review

Macrolides vs tetracycline

Quality of life Drug resistance/microbial sensitivity Serious adverse events Lung function Hospitalisations Adverse events/side effects Number of participants colonised with P aeruginosa · patients with chronic obstructive pulmonary disease

The review found no eligible studies for this question.

1 finding from 1 review

Quinolone vs tetracycline

Quality of life Drug resistance/microbial sensitivity Serious adverse events Lung function Hospitalisations Adverse events/side effects Number of participants colonised with P aeruginosa · patients with chronic obstructive pulmonary disease

The review found no eligible studies for this question.

1 finding from 1 review